Cardiovascular Outcomes and Risks After Initiation of a Sodium Glucose Co-Transporter 2 Inhibitor: Results From the EASEL Population-Based Cohort Study.

Conclusions : In this high-risk cohort, initiation of SGLT2i was associated with lower ACM, HHF, and MACE and higher BKA risk. Findings underscore the potential benefit and risks to be aware of when initiating SGLT2i. It remains unclear whether the BKA risk extends across the class of medication as the study was not powered to make comparisons among individual treatments.
PMID: 29133607 [PubMed - as supplied by publisher]

Source: Circulation - November 13, 2017 Category: Cardiology Authors: Udell JA, Yuan Z, Rush T, Sicignano NM, Galitz M, Rosenthal N Tags: Circulation Source Type: research